1. Abbott A, Dolgin E (2016) Leading Alzheimer’s theory survives drug failure. Nature 540:15–16. https://doi.org/10.1038/nature.2016.21045
2. Alzforum (2021) Therapeutics: solanezumab. 4 Aug 2021. https://www.alzforum.org/therapeutics/solanezumab. Accessed 23 Jan 2023
3. Alzforum (2023) Therapeutics: crenezumab. 6 Jan 2023. Accessed 10 Jan 2023
4. Armstrong A (2022) Biogen shoves Aduhelm to the side. It’s time for lecanemab. FIERCE Biotech. 4 May 2022. https://www.fiercebiotech.com/biotech/biogen-shoves-aduhelm-side-its-time-lecanemab
5. Biogen (2022a) Eisai completes rolling submission to the U.S. FDA for biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway [Press Release]. 9 May 2022. https://investors.biogen.com/news-releases/news-release-details/eisai-completes-rolling-submission-us-fda-biologics-license. Accessed 23 Jan 2023